2012-2013 NIH CAP Company Descriptions

Tucson,AZ|4dtechnology.com	**4 D Technology Corp** Research Tools Katherine Creath kathy.creath@4dtechnology.com (520) 294-5600
4D Technology Corp. is an innovative leader in optical measurement technology. Our key technology is a patented phase measuring camera utilizing a pixelated polarizer mask for applications in astronomy, interferometry, optical metrology, remote sensing, and now for biological imaging. Over the last 10 years, we have developed a number of products to serve industrial and research markets in aerospace, astronomy and optics manufacturing. The goal for this current project is to expand our business into the biological imaging market by developing an instrument utilizing our state-of-the-art technology into a research tool for the study of live cells.	

Little Rock,AR	**Acetaminophen Toxicity Diagnostics** Diagnostics Laura James jameslaurap@uams.edu (501) 364-1418
ATD, LLC has developed a rapid assay for the detection of acetaminophen protein adducts in clinical blood samples.	

Bellefonte,PA|actuatedmedical.com	**Actuated Medical, Inc** Medical Devices Maureen Mulvihill maureen.mulvihill@actuatedmedical.com (814) 355-0003
AMI develops and manufactures state-of-the-art medical devices that incorporate controlled motion technologies. Our commercial-ready innovations are FDA cleared and CE Marked with a global presence. Simply stated, our products allow clinicians to perform faster, easier and safer procedures. We engage our staff of skilled engineers, designers, and fabrication experts to develop patent-protected manufactured products that address important clinical needs and attract commercialization partners. We finance this work largely through non-dilutive grant and commercial partnership funding. We have developed manufacturing facilities that can supply the device components or products to OEM partners on a commercial scale.	

Plymouth,MI|advaitacorporation.com	**Advaita Corporation** Other Andrew Olson andrew@advaitacorporation.com (734) 922-0110
Advaita Corporation is a development-stage company with headquarters near Ann Arbor, Michigan. A spinout from Wayne State University, Advaita is focused on developing bioinformatics tools (software) for the research and pharmaceutical industries. Through its $2.2M NIH STTR Phase II award, Advaita has developed a software platform for the analysis of data from high-throughput microarray experiments. We are now entering the commercialization phase of the development plan. We have two active licensees and are planning on launching a marketing campaign at the beginning of the year. We are seeking assistance with this phase of the plan.	

Reston,VA|www.aframedigital.com	**AFrame Digital** Healthcare IT Cindy Crump ccrump@aframedigital.com (571) 308-0147
AFrame Digital delivers advanced telemonitoring solutions with data analytics that integrate patient safety with remote health monitoring to support patients and residents in hospital, long-term care, senior living and home settings. Our end-to-end MobileCare Monitor solution helps caregivers take a more proactive approach to care, promotes coordination across care settings, and enhances the independence and safety of seniors, patients managing chronic conditions and other at-risk individuals. We are installed in senior living and rehabilitation hospitals and individual homes in the U.S. and Australia.	

Lexington,KY|ALKYMOS.com	**ALKYMOS, Inc.** Medical Devices Robert Yokel Robert.Yokel@ALKYMOS.com (859) 257-6957
The mission of ALKYMOS is to design, synthesize, evaluate and manufacture chelators and chelator-based devices for laboratory, industrial, animal and human applications. We are focusing on the development of a single-use flow-through immobilized-chelator containing device to remove most of the aluminum from calcium gluconate, a component of total parenteral nutrition solution. These solutions are given intravenously to premature infants, who do not tolerate oral feeding, to provide all of their fluid and nutritional requirements. Aluminum is present as a contaminant. It has no beneficial effect in humans, but can produce toxicity to several organ systems.	

Fremont,CA|www.arborvita.com	**Arbor Vita Corporation** Medical Devices Johannes Schweizer Johannes.Schweizer@ArborVita.com (408) 410-8486
Founded in 1998, privately-funded Arbor Vita Corporation (AVC) focuses on developing novel diagnostics and therapeutics using a propietary PDZ proteomics platform to improve healthcare worldwide. AVC was the first to obtain FDA clearance for a rapid test H5N1 Avian Flu in 2009 and is now moving its first cervical cancer biomarker test, from AVC's suite of tests based on its OncoE6(TM) test platform, into commercialization. AVC also maintains a program to develop a treatmetn for HPV-induced cancers. AVC plans to start commercialization of its cervical cancer biomarker test in 2013.	

Trenton,NJ|www.artannlabs.com	**Artann Laboratories, Inc.** Medical Devices Noune Sarvazyan nsarvaz@artannlabs.com (512) 996-8565
Artann Laboratories is dynamic company with the mission of early stage development and validation of novel biomedical products. Artann developed numerous technologies in medical diagnostics. Since 1995 Artann has built a solid intellectual property foundation for its technologies with 41 issued and pending US patents. Further, the company has established a sound record of bringing new technologies from the level of an academic idea into the stage of functional prototypes, clinical validation and regulatory clearance. To date, Artann licensed five proprietary technologies to private and public companies to carry out the commercialization of its products.	

San Mateo,,CA|www.artielle.com	**Artielle Immunotherapeutics Inc.** Pharmaceuticals Gregory Burrows ggb@ohsu.edu (650) 401-2007
Artielle Immunotherapeutics, Inc. is a clinical stage, venture-backed company developing a novel class of drugs termed Recombinant T-cell receptor Ligands, 'RTLs,' to treat a wide range of T-cell mediated inflammatory diseases including multiple sclerosis (MS), celiac disease, type 1 diabetes, rheumatoid arthritis, uveitis, and graft vs. host disease (GVHD). Data from a recently completed Phase 1 safety study with lead compound RTL1000 in MS indicates that the drug is safe and well-tolerated. Artielle's platform technology is the subject of a worldwide exclusive license with Oregon Health & Science University that covers all classes of RTLs and all therapeutic applications.	

Lakewood,NJ|avivbiomedical.com	**Aviv Biomedical, Inc.** Medical Devices Glen Ramsay glen@avivbiomedical.com (732) 370-1300
In 1975 Aviv Associates licensed technology from Bell Laboratories for the measurement of zinc protoporphyrin (ZPP). The ZPP instrument was fully commercialized by Aviv, approved by the FDA, and continues be offered by Aviv. In 1984 Aviv Biomedical was incorporated and all licenses from Bell Labs were transferred. This includes the technology to develop a bilirubin hematofluorometer. Currently, Aviv has received NIH Phase I & II funding for the commercialization of the bilirubin technology as a point-of-care screening instrument. In addition, Aviv is a self-sufficient company, providing a line of high-end, research grade instruments for universities, companies, and government laboratories.	

Rockville,MD|www.bio-quick.com	**Bio-Quick Corp.** Medical Devices Wei-Sing Chu chuzhu@yahoo.com (301) 675-8666
Bio-Quick Corp has completed the proof-of-concept stage and has constructed prototype devices. By now, two medical instrument companies, Ventana/Roche and Leica/Danaher, have evaluated US-FFPE technology and expressed interests for possible licensing this technology. Recently, General Electronics (GE) also shows great interest in Bio-quick's US-FFPE technology and Cell array quality control slides. A validation study has been carried out in GE's global research center and results are promising for both technologies. If the collaboration proves successful, the commercialization of our technology will be greatly promoted. Bio-Quick is now seeking the guidance and the strategies to collaborate with big companies.	

Cambridge,MA|biosensics.com	**BioSensics LLC** Medical Devices Ashkan Vaziri ashkan.vaziri@biosensics.com (617) 270-6813
BioSensics is a research and product development company specializing in wearable sensors for healthcare. In addition to the products we sell, we offer custom telehealth solutions and algorithm licensing opportunities for corporate, government, and academic partners.	

Botani PHARM® Integrating Plants, Science & Health Candler,NC|botanipharm.com	**BotaniPharm, LLC** Pharmaceuticals Steve Henson shenson@wcu.edu (706) 259-7647
BotaniPharm, LLC is grower owned botanical product processing company which specializes in the production and processing of high value forest grown plants with medicinal properties.	

Bright Cloud International Corp Highland Park,NJ|brightcloudint.com	**Bright Cloud International Corp** Medical Devices Grigore (Greg) Burdea CTT (908) 406-9334
Bright Cloud International(BCI) is a medical device and software development company. We design, patent, and will market advanced computerized rehabilitation systems. There is an unmet need of many patient populations for motivating, intensive, mufti-faceted therapy. BCI is the only company to combine physical, cognitive and emotive rehabilitation into a single-point-of-care, customized, game-based therapy. BCI is also the first company to offer a robotic rehabilitation platform to train the arm and hand, while reducing depression and improving memory. We increase intensity of therapy sessions (benefiting the patient), while reducing clinical manpower (benefiting managed care providers). We make therapy fun, and substantially improve clinical outcomes.	

Buffalo Grove,Il|brightoutcome.com	**BrightOutcome Inc.** Healthcare IT DerShung Yang dershung.yang@brightoutcome.com (847) 419-9288
BrightOutcome focuses on developing innovative healthcare IT (HIT) solutions by applying patient-reported outcomes (PRO) technologies in a variety of clinical contexts to promote self-management, foster shared decision-making, and ultimately improve patient outcomes. Our primary product is a SaaS-based PRO management solution, and we have applied it to cancer symptom management, cancer patient portal, cancer screening decision support, and weight management for disabled persons. We collaborate with more than a dozen top-rated research and patient-care institutions in product development/validation under numerous competitive NIH/CDC SBIR grants/contracts and the prestigious ARRA Challenge Grant.	

Lebanon,NH|celdaramedical.com	**Celdara Medical** Biotechnology Yolanda Nesbeth yn@celdaramedical.com (617) 320-8521
Celdara Medical's mission is to save lives, improve quality of life, and deliver superior returns to shareholders through identification and commercialization of early-stage inventions and discoveries. We work (through Affiliates etc.) with 11 academic institutions representing over $2B/y in NIH funding. As individual Programs within CM grow, advance, and are venture backed, we spin out daughter companies with dedicated management teams. The first of these spinouts is currently being structured. Our core competencies lie in the earliest stages of technology commercialization; our lean business model affords us excellent returns without the need to grow into a large or public company.	

Rockville,MD|clarassance.com	**Clarassance** Biotechnology Aprile Pilon aprile.pilon@clarassance.com (301) 452-2899
Clarassance is a clinical stage biotechnology company developing protein drugs to treat respiratory diseases. There have been no truly novel drugs introduced in the respiratory field in decades and Clarassance's products from the CC10 family of immune-regulatory proteins will address unmet needs in treating respiratory conditions.	

Research Triangle Park,NC|cognosci.com	**Cognosci, Inc.** Pharmaceuticals Feng-Qiao Li fli@cognosci.com (919) 765-0028
Cognosci, Inc. was founded by Dr. Michael Vitek in 2000 at Research Triangle Park, NC as a spinout from Duke University and obtained an exclusive license to the core technology - Apolipoprotein E-mimetic peptides from Duke. Extensive studies by Cognosci Scientist and collaborators have demonstrated apoE-mimetics exert a variety of beneficial activities in anti-inflammation, neuroprotection, remyelination and neuroregeneration. We have completed lead identification and preclinical proof of concept for treatment of antoimmune disease Multiple Sclerosis as a neuroreparative strategy. To date, Cognosci has funded operation through NIH SBIR/STTR program and DOD grants and has not raised any dilutive capitals. Cognosci is now pursuing an equity investment to advance our lead candidate through IND safety/toxicity study, Phase I and II clinical trials.	

Cambridge,MA|dnamedinstitute.com	**DNA Medicine Institute** Diagnostics Eugene Chan echan@dnamedinstitute.com (617) 233-7656
DMI is developing and commercialization a small point-of-care medical device that allows multiple different tests off a single drop of blood. Through NHLBI Phase I and II funding, it is developing a complete blood count (CBC) with 3-part differential. This represents > $600M market and is largely untapped because of the lack of technology to address this need. DMI was founded by Eugene Y. Chan, MD, an entrepreneur-innovator. DMI has 10 employees, was founded in 2007, and is currently in the prototype phase. DMI is expected to file for FDA approval in 2014 for its initial assays and commercialization shortly thereafter.	

Bellevue,WA|drvtechnologies.com	**DRVision Technologies LLC** Research Tools Sam Alworth sama@drvtechnologies.com (425) 653-5589
DRVision Technologies LLC was established in May 2008 to carry on the business of SVision LLC (established 1999) with a minority investment from Nikon America Inc. DRVision / SVision is a technology pioneer with a comprehensive technology and IP position. We have 44 issued and 10 pending US patents broadly protecting image analysis, target search, machine vision, machine learning, pattern recognition, and related interfaces and applications. DRVision has two active NIH Phase II projects.	

 San Diego,CA|electronicbio.com	**Electronic BioSciences** Research Tools Geoffrey Barrall gbarrall@electronicbio.com (858) 373-0232
Electronic BioSciences combines expertise in biologically based platforms with exceptionally low noise electronics in order to produce sensitive systems for nanopore and ion channel measurements with potential applications in DNA sequencing, ion channel characterization, and chemical sensing. The company's headquarters is a combined office and laboratory facility in the Sorrento Valley area of San Diego with multiple laboratories for protein expression, ion channel conductance measurement, electronics development, and glass nanopore membrane (GNM) fabrication. EBS has a satellite laboratory in the University of Utah's Research Park in Salt Lake City.	

Arvada,CO|flexfilmkinetics.com	**Flex Films Group LLC** Other Jon VonOhlsen jonvo@flexfilmkinetics.com (303) 395-3300
Flex Films Group LLC was formed to further develop the thin-film flexible substrate technology developed for the endoscopic end-effectors.	

Portland,OR|gamma-therapeutics.com	**Gamma Therapeutics, Inc.** Diagnostics David Farrell dfarrell@gamma-therapeutics.com (503) 222-2313
Gamma Therapeutics is a Portland, OR biotechnology venture developing a novel class of biopharmaceutical and diagnostic test solutions for the cardiovascular disease industry based upon a natural clotting protein in blood called Gamma Prime Fibrinogen. The Gamma Therapeutics product line includes its provisional-patented flagship product, GammaCoeur™, a VTE and CVD risk diagnostic assay; GammaSeal™, a patented, high strength post-surgical incision sealant; Gammarin™, a patented non-immunogenic blood anti-coagulant, and GammaTF™, a rapid hemostatic dressing that induces blood coagulation in less than one minute.	

St. Paul,MN|gel-del.com	**Gel-Del Technologies, Inc.** Medical Devices David Masters dmasters@gel-del.com (651) 209-0707
Gel-Del Technologies, Inc. is a biomaterial and medical device manufacturing company that was founded in 1999. More than $11M has been invested to advance our translational regenerative biomaterial, including a FDA-approved, dermal filler clinical trial. The company owns all of its IP and is seeking commercialization partners for technology licensing or acquisition.	

Irwindale,CA|www.genefluidics.com	**Genefluidics** Medical Devices Vincent Gau vgau@genefluidics.com (626) 263-3060
Genefluidics was incorporated in 2000 to develop a fast, accurate, and simple testing system for improving worldwide healthcare. By integrating novel molecular analysis and microfluidic technologies, the company's revolutionary platform enables complex tests that are normally performed only by skilled technicians in a laboratory to be performed by anyone, anywhere. Genefluidics is committed to improving the quality of human life with advanced engineering technologies. Genefluidics has the product lines and experience in microfluidic point-of-care (POC) device and robotic system, as well as the established processes in rapid fabrication and assays to address the challenges in implementing raw-specimen-to-result multiplexed molecular analysis.	

Newton,MA|ginerinc.com	**Giner, Inc.** Medical Devices Andrew Belt abelt@ginerinc.com (781) 529-0504
Giner, Inc. is a world-class electrochemical technology company founded in 1973. Giner R&D clients include NASA, General Motors, DoD, NIH, and Boeing. Over the last 5 years, Giner has commercialized a series of products in partnerships, including oxygen generation stacks for nuclear submarines, transdermal alcohol sensors, and small and large hydrogen generation systems. Giner now generates 40% of its ~$13M annual revenues (2011) from manufacturing. Giner will spin-off Giner Medical to concentrate on developing the Giner oxygenation life science and medical products to include the persufflation organ preservation system that is the focus of this application.	

Guided Therapeutics™ 5835 Peachtree Corners East, D · Norcross, GA 30092 Norcross,GA|guidedinc.com	**Guided Therapeutics Inc.** Medical Devices Manju Venugopal MVenugopal@guidedinc.com (770) 242-8723
Guided Therapeutics, Inc. is developing a rapid and painless testing platform for the early detection of disease based on its patented biophotonic technology that utilizes light to detect disease at the cellular level. The Company's first planned product is the LuViva® Advanced Cervical Scan, to detect cervical disease instantly and at the point of care. Guided Therapeutics has also entered into a partnership with Konica Minolta to develop a non-invasive test for the early detection of esophageal cancer using the technology platform. Guided Therapeutics has a Phase II grant for the development of a sensor for non-invasive measurement of levels of cortisol in ISF.	

INTRINSIC LIFESCIENCES The BioIron Company La Jolla,CA|www.intrinsiclifesciences.com	**Intrinsic LifeSciences, LLC** Diagnostics Mark Westerman mwesterman@intrinsiclifesciences.com (858) 459-1758
Intrinsic LifeSciences (ILS) is an early-stage diagnostics company focused on the development of FDA-approved medical diagnostic devices for the prediction of genetic iron disorders and iron-related diseases. Our lead diagnostic target is hepcidin, the key hormone regulating dietary iron absorption, iron recycling via macrophages, and iron transport from hepatocyte.	

INVIVOSCIENCES Madison,WI|www.invivosciences.com	**InvivoSciences LLC** Biotechnology Ayla Annac aannac@invivosciences.com (608) 628-8035
InvivoSciences provides phenotypic compound screening services for first-in-class drug discovery and drug repositioning. Our- 2012 Edison Award winning- engineered tissue based high content analysis assay evaluates efficacy and safety of compounds through their effects on physiological properties of tissue constructs. Those constructs are fabricated using human cells, including cardiomyocytes derived from induced pluripotent stem cells (iPSCs). These constructs mimic physiological properties of cardiac and skeletal muscles as well as connective tissues. The same functional parameters (i.e., biomarkers) that are used in animal studies and clinical trials are assessed for compound-induced changes in physiological properties of human tissue constructs. In support of National Institute of Health, an application of the technology in comprehensive cardiac safety assessment has been in the late phase of validation.	

K&A WIRELESS, LLC Albuquerque,NM|www.ka-wireless.com	**K&A Wireless, LLC** Medical Devices Kamil Agi kagi@ka-wireless.com (505) 338-2380
K&A Wireless markets, manufacturers and delivers video transport solutions to the first responder, law enforcement and military markets. Since its inception in 1998, the platforms and products developed at K&A Wireless, LLC bring a new immediacy and capacity to capture and deliver video information. It helps clients improve their productivity in mission-critical tasks and operations by acquiring video data from anywhere and delivering it to anywhere, either in real time through image processing and/or wireless transmission, or for analysis in the future during training or review through video capture and storage.	

 Export,PA|www.ligsciences.com	**LIG Sciences, Inc.** Other Kevin Smith ksmith@ligsciences.com (724) 539-8310
LIG Sciences, Inc., a C corp, was originally founded in 2005 and after a bankruptcy of the parent company in 2009, was restarted by the principles of NanoDynamics Life Sciences, Inc., now renamed LIG Sciences, Inc.. The company was relocated to more cost effective space, which includes high bay space for future manufacturing, in an industrial park in Export, PA that is 20 miles from Pittsburgh. The company's main focus is to develop biotechnical useful materials, nanomaterials and/or coatings through funded SBIR programs or industrial partners, fabricate the key component of this IP funded work and sell the component to larger industrial customers, in some cases those that were involved during the SBIR program. If manufacturing is found not to be feasible then licensing opportunities will be pursued.	

 College Station,TX|www.lynntech.com	**Lynntech, Inc.** Medical Devices JoAnne Goodnight joanne.goodnight@lynntech.com (979) 764-2222
Lynntech is a private Texas "C" corporation founded in 1987. Lynntech's mission is to provide efficient, reliable, and innovative technology solutions to the global community. We incorporate all stages of the R&D cycle, offering conceptual design, experimental analysis, prototype creation, market positioning and commercial production. Lynntech's business model is to develop proprietary technology for commercialization through strategic alliances and/or licensing agreements. Our capabilities encompass five major focus areas: Life Sciences (with a focus on Medical Devices and Diagnostics); Energy & Power; Materials Sciences; Cyber-physical Systems; and Industrial Sciences. Lynntech is currently capitalized by shareholder equity, retained earnings, and debt.	

Eugene,OR|www.markergene.com	**Marker Gene Technologies, Inc.** Diagnostics Michael Ignatius mignatius@markergene.com (541) 342-3760
Marker Gene Technologies has developed and manufactures over 300 different life-science products. The company specializes in Live Cell analysis kits and high quality Fluorescent Reagents, Enzyme Assays, Carbohydrates, Lipids, Labeling Reagents, Substrates and Expression Vectors. The company's products are sold worldwide primarily through a worldwide network of life science distributors and by direct sales over the internet. The company is based in Eugene, Oregon and maintains close ties with the University of Oregon, Life Technologies / Invitrogen Corp., OHSU and the Oregon Cancer Center. The company currently employs 10 full and part time individuals.	

Arlington Heights,IL|www.matsdev.com	**Materials Development, Inc.** Medical Devices Richard Weber rweber@matsdev.com (847) 612-8597
Materials Development, Inc., (MDI) was formed in 2006. Its mission is: "To develop and provide innovative materials and process technologies to clients in the global glass and ceramics industries." The company provides optical materials products, extreme environment instrumentation, consulting, and business assistance. MDI's clients include national laboratories, universities and industrial companies. The company specializes in working with customers to develop solutions to problems in optimization of high performance optical materials and extreme environment materials handling. MDI has research and manufacturing facilities and the company is staffed by an experienced team of scientists, engineers and technology business mangers.	

Saint Louis,MO|mediomics.com	**Mediomics, LLC** Research Tools Yie-Hwa Chang yiechang@mediomics.com (314) 971-3026
Mediomics' mission is to develop robust, highly specific and sensitive molecular sensors that can be utilized in research, manufacturing process controls, medical diagnostics and pathogen detection. It will achieve this mission by leveraging government support with private funds to develop and validate the bioassay platform technology for multiple applications which will then be commercialized directly and through distributors to end-users, in the case with bioassays, and via collaborations with strategic partners for clinical diagnostics and select market applications.	

Portland,OR|www.metabolicnutritionals.com	**Metabolic Nutritionals** Medical Devices Scott Buckley theron@reed.edu (503) 705-3089
Metabolic Nutritionals is a small company that specializes in the field of medical foods for the treatment of inborn errors of metabolism and in problems of infant feeding. The long-term goal of our work is to develop a new quantitative tool for the assessment of neurodevelopmental function in neonates that could be used for prognosis of long-term outcome in high-risk infants such as premature infants or those with birth defects.	

Delaware,OH	**MetalloPharm LLC** Pharmaceuticals Ada Cowan acowan@metallopharm.com (740) 917-5108
MetalloPharm is a drug discovery company that is developing a new class of pharmaceutically active compounds based on catalytic metallodrugs that mediate irreversible destruction of therapeutic targets, making drug resistance less likely to develop. The proprietary platform is versatile and applicable to a large array of disease indications (anti-infectives, hypertensive agents, cancer, amyloid diseases), as well as a variety of therapeutic approaches (small molecules, antibodies). An innovative pharmaceutical approach to the treatment of bacterial and viral infections would provide physicians with new tools to treat increasingly challenging conditions. Proof of concept testing has been accomplished for the hepatitis C virus and antimicrobials.	

New Haven,CT|www.mnimaging.com	**Molecular NeuroImaging LLC** Diagnostics George Zubal gzubal@mnimaging.com (203) 401-4300
Molecular NeuroImaging, LLC (MNI) is a neuroimaging services company specializing in the efficient application of scintigraphic biomarkers in drug development and clinical research for neurodegenerative and neuropsychiatric disorders. Molecular NeuroImaging is a limited liability corporation that was organized in 2000 to further research into neurodegenerative disorders such as PD and AD.	

Santa Cruz,CA|www.monarchmedia.com	**Monarch Media, Inc.** Other Chris Bush chris@monarchmedia.com (831) 457-4414
Monarch Media is a leader in delivering custom eLearning and mLearning solutions across the globe. For 15 years our management team has helped leading corporations, government agencies, universities, and nonprofits accomplish their training and educational goals by blending technology solutions with instructional and graphic design expertise to create effective online learning experiences.	

Columbia,MO|nanoparticlebiochem.com	**Nanoparticle BioChem, Inc.** Pharmaceuticals Anandhi Upendran upendrana@missouri.edu (573) 424-2666
Nanoparticle Biochem Inc (NBI) is a nanotechnology based company started from the intellectual property generated by team of scientists from University of Missouri. From the time of inauguration, NBI has successfully capitalized on funding from several federal state agencies and private pharma companies for developing cancer diagnostic and therapeutic nanotechnologies for solving unmet key clinical issues. NBI has developed a novel nano-therapeutic agent NBI-29 and is currently conducting pre-clinical trials in large animal models for treating prostate tumors. This trial is funded by NCI/NIH under SBIR Phase II contract mechanism. In addition, NBI manufactures and sells an array of nanoparticle-based products.	

Columbia,MO	**Nanova, Inc.** Medical Devices Meng Chen chenmeng@nanovamed.com (573) 529-9252
Nanova, Inc. is a small medical device company that designs, patents, fabricates, and markets medical devices in cardiovascular, orthopaedic, dental, and other surgical or non-surgical niche markets. Our key product development is primarily based on non-thermal plasma technology, biomimetic nanocomposites technology, and nanotechnology based sensing technology, which can provide complete solutions for several critical problems in the above fields.	

Raleigh,NC|www.nanovectorinc.com	**NanoVector, Inc.** Pharmaceuticals Albert Bender abender@nanovectorinc.com (919) 607-4515
NanoVector is using a unique biologic nanoparticle to develop targeted cancer therapeutics and diagnostics for the $48B/yr global cancer market. With targeting, anti-cancer agents concentrate in a cancer cell nucleus resulting in extremely high efficacy, while diminishing toxicity to healthy cells, minimizing unpleasant side effects.	

Bethesda,MD|newhealthsciences.com	**New Health Sciences, Inc.** Medical Devices Martin Cannon martin.cannon@newhealthsciences.com (301) 493-4586
New Health Sciences, Inc. (NHSi) is developing Hemanext, a novel technology to deliver red blood cells (RBCs) of higher efficacy for transfusion therapy. Hemanext is an RBC storage system that processes and maintains blood in an anaerobic state over the 42 FDA regulated storage period. Removing oxygen from the storage process has the effect of maintaining "fresh" characteristics longer than conventional methods and thereby reducing some of the harmful effects of blood transfusions.	

OLIGOMERIX, Inc. New York,NY|www.oligomerix.com	**Oligomerix, Inc.** Pharmaceuticals James Moe jmoe@oligomerix.com (212) 568-0365
Oligomerix was founded in 2006 with NIH and investor funding to advance its drug discovery program for Alzheimer's disease and related tauopathies by targeting tau oligomers that cause disease symptoms and progression. Based on its discovery that tau oligomers have an intrinsic proteolytic activity leading to self-degradation and cleavage of other proteins, the Company is developing small molecule drugs to inhibit the formation of tau oligomers and to inhibit their proteolytic activity. Antibodies are also being developed for immunotherapeutics and biomarkers targeting tau protease. Oligomerix is in advanced discussions (CDA) with pharmaceutical companies to license these programs and co-develop therapeutics.	

Austin,TX|www.omegaoptics.com	**Omega Optics Inc** Diagnostics Ray Chen ray.chen@omegaoptics.com (512) 825-4480
Since its initiation in 2001, Omega has been actively involved in optical communications/interconnects/sensors research/development work where arrays of products have been developed from internal R&D and SBIR/STTR efforts. Polymer based planar light-wave circuit, DWDM and silicon nano-photonics for integrated optics and chemical and biological sensing are core technologies of Omega Optics.	

Atlanta,GA	**OpenCell Technologies, Inc.** Research Tools John Meacham jmm@opencelltech.com (404) 273-7866
OpenCell Technologies was founded in 2008 by a team of Georgia Tech researchers to develop intracellular nanomaterial delivery devices. The core technology, which evolved from investigations into Life Sciences applications of novel micromachined ultrasonic fluid atomizers, is essential to realizing an efficient, scalable and low-cost transfection tool that is suitable for use with important yet difficult-to-transfect cells (e.g., primary and cancer stem cell cultures). Unlike currently available products (e.g., numerous electroporators), the OpenCell technology features precise control of biophysical actions on a single-cell basis while processing millions of cells per second, thus addressing many shortcomings of existing transfection methods.	

East Providence,RI|www.protherabiologics.com	**ProThera Biologics** Other Yow-Pin Lim yplim@protherabiologics.com (401) 301-2046
ProThera Biologics is a development stage bio-therapeutics Company based in East Providence, Rhode Island. The Company was founded in 2002 and has developed a proprietary technology that uses naturally occurring serine protease inhibitors (Inter-alpha Inhibitor proteins, IAIP) to treat life-threatening conditions, both in biodefense applications such as anthrax intoxication as well as a wide range of clinical indications resulting from infection and severe systemic inflammation.	

Rensselaer,NY|www.pulmokine.net	**Pulmokine Inc.** Pharmaceuticals Lawrence Zisman lz@pulmokine.net (518) 573-8315
Pulmokine is a Biopharmaceutical Company whose mission is to develop new treatments for pulmonary arterial hypertension and related disorders.	

Huntsville,AL|www.q-track.com	**Q-Track Corporation** Healthcare IT Eric Richards e.richards@q-track.com (256) 489-0075
Q-Track's provides indoor location and tracking of assets and persons using proprietary Near Field Electromagnetic Ranging (NFER®) technology. Our solutions yield substantial competitive advantages in the Real Time Location Systems (RTLS) market by providing high accuracy at low costs.	

Versailles,KY|re3medical.com	**Re3 Medical, LLC (a subsidiary of customKYnetics, Inc.)** Medical Devices Chuck Mix mix@re3medical.com (859) 879-3718
Re3 Medical, LLC is a rehabilitation solutions company, specializing in the ortho-rehabilitation and neuro-rehabilitation markets. The company was organized in 2012 as a subsidiary of customKYnetics, Inc., with the specific focus of commercializing the technologies that had been developed through customKYnetics' 12-year research history.	

Flagstaff,AZ|senestech.com	**SenesTech, Inc.** Biotechnology Loretta Mayer loretta.mayer@senestech.com (928) 862-7329
SenesTech is a platform biotechnology company specializing in reproductive physiology for humane animal population management. Our primary objective is to develop products that will sterilize animals in a non-surgical, non-toxic and environmentally neutral manner. We believe there is a vast untapped global market for our products. We expect to evolve and continue as a research and development company marketing products through distribution networks for humane animal population management. However, since our products represent a true market innovation, it is not unrealistic to expect that SenesTech could become a target for acquisition.	

Bozeman,MT|sensopath.com	**SensoPath Technologies Inc.** Pharmaceuticals Charles Spangler spangler.charles@sensopath.com (406) 587-6338
SensoPath Technologies is an early stage biosensor and cancer therapeutics company that designs, synthesizes and sells custom biosensor surfaces for use in a variety of detectors. SPT also markets a variety of custom chemicals, and fluorescent reporter molecules. Most recently SPT has developed a porphyrin-based cancer therapeutic that incorporates a targeting peptide that directs the ensemble to over-expressed receptor sites on the tumor surface, plus a Near-infrrared imaging agent that allows the tumor to be 3D imaged and laser irradiated in the tissue transparency window, which kills the tumor in a one-day outpatient setting and eliminates the need for surgery, follow-on chemotherapy or radiation treatment.	

Malvern,PA|shifabiomedical.com	**Shifa Biomedical Corporation** Pharmaceuticals Sherin Abdel-Meguid sherin@shifabiomedical.com (610) 400-1243
Shifa Biomedical Corporation (Shifa) is a privately held biopharmaceutical company dedicated to the rapid, cost-effective development of drugs for the treatment of cardiovascular diseases. Incorporated in 2006, Shifa has much of the expertise essential for the rational design of small molecule drugs. It is being led by an internationally-known team of scientists, with considerable expertise in early stage pharmaceutical discovery. Shifa is supported by private funds, collaborations and research grants. Shifa has received several NIH Phase I and Phase II SBIR grants.	

 Fort Collins,CO|pai-smartmove.com	**SmartMove aka. Physical Activity Innovations, Inc.** Medical Devices Harry Baeverstad harry.baeverstad@pai-smartmove.com (970) 231-5682
Physical Activity Innovations (PAI) develops coaching solutions which encourage people to live more actively. Founded in Fort Collins, CO in 2008, PAI's vision is to be the leading provider of high-technology solutions that motivate and encourage people to live more active lifestyles. Our mission is to capture the high end segment of the physical activity monitoring and coaching devices market within the next 3 years.	

 Bethesda,MD|surgisense.com	**Surgisense Corporation** Medical Devices Jason Zand jzand@surgisense.com (202) 777-3626
Surgisense's mission is to improve patient care by enhancing the surgeons' perspective through the use of sensing surgical instruments. Multimodality sensors, incorporating proprietary technology that directly measures tissue oxygenation, enable real-time assessment of tissue viability, and propensity to heal. The Company's initial technology, the SAVE System, strives to reduce the most dreaded complication of gastrointestinal surgery: the anastomotic leak; however our proprietary sensing approach allows for platform extension into many clinical applications. The technology's primary value proposition is in improving patient outcome and quality of life; the value to the healthcare system derives from reduction of costs associated with procedural failures.	

Blacksburg,VA|synthonicsinc.com	**Synthonics Inc.** Pharmaceuticals Kenneth Slepicka kslepicka@synthonicsinc.com (708) 209-1907
Synthonics is a specialty pharmaceutical company focused on the discovery and development of drugs that incorporate our proprietary metal coordination chemistry. Metal coordination entails attaching a pharmaceutically acceptable metal, such as zinc, bismuth or magnesium, to an active pharmaceutical agent to create a new and more effective drug (a metal coordinated pharmaceutical or "MCP"). Metal coordination offers tremendous flexibility, as it employs multiple binding sites by which drugs and adjuvants can be attached to metals to impart the desired pharmacokinetics. The USPTO has awarded several MCP patents and the company intends to license its MCP's to other pharmaceutical companies.	

Seattle,WA|talariainc.com	**Talaria Inc** Other Charles Chabal chabal@talariainc.com (206) 748-0443
Talaria Inc. is a medical research company. Talaria has been in business since 1993. Initially funded through the SBIR program Talaria's revenues are largely from commercial sales and consultation of its medical software services. The founders of the company are board certified pain management physicians. The heater project is the company's first medical device product. It is likely that this device, sold as a non-prescription, consumer health product will be licensed to a separate company.	

Chapel Hill,NC|web.telesage.com	**TeleSage, Inc.** Diagnostics Melanie Elliott Wilson mwilson@telesage.com (919) 942-8849
TeleSage has pioneered the development of automated survey administration and clinical reporting technologies for behavioral health research and clinical practice. TeleSage, Inc. plans to continue as a stand-alone company dedicated to the development and sales/licensing of high-quality IP.	

Columbia,MO	**Tensive Controls, Inc.** Pharmaceuticals Kenneth Gruber gruberke@missouri.edu (909) 210-1441
Tensive Controls is an early stage biotechnology-pharmaceutical company that is commercializing proprietary peptide technology, with a major focus on melanocortin-based drugs to treat cachexia. Cachexia is a disease characterized by anorexia and a hyper-metabolic state that eventually results in multi-organ failure. Melanocortin antagonist peptides reverse cachexia, but peptides as a class are notoriously unstable (short duration of action) and have no oral activity. Tensive Controls' technology allows peptides to be formulated and absorbed just like typical drugs. Ultimately, our company will extend our technology to other potentially therapeutic peptides, with the goal of producing orally active peptide drugs.	

Austin,TX|terapio.com	**Terapio Corporation** Pharmaceuticals Curt Bilby cbilby@terapio.com (512) 514-6760
Terapio is a biopharmaceutical company developing therapeutics based on the RLIP76 protein. Initial applications include developing the RLIP76 protein as a medical countermeasure for radiation exposure and chemical threats to civilian, military, and first responder populations. The RLIP76 protein primarily works though the oxidative stress pathway and provides benefit as both a prophylactic and post exposure treatment.	

Houston,TX|tomowave.com	**TomoWave Laboratories, Inc.** Medical Devices Alexander Oraevsky aao@tomowave.com (713) 270-5393
TomoWave develops biomedical imaging, sensing and monitoring devices based on proprietary laser optoacoustic / laser ultrasonic technologies invented in house. The laser optoacoustic ultrasonic imaging system represent a platform technology for a wide variety of medical applications in cancer diagnostics and treatment and angiography. The present focus is commercialization of the three-dimensional tomography system for preclinical research and development of a commercial prototype of the comprehensive modality for breast cancer screening (detection), diagnostics and monitoring of treatment. The goal of participating in LARTA CAP is to receive investment, accelerate commercialization and establish gradually increasing sales.	

Baltimore,MD|chadis.com	**Total Child Health, Inc.** Healthcare IT Barbara Howard bhoward@chadis.com (410) 377-0380
Total Child Health licenses CHADIS, a web-based previsit screening, decision support and post-visit engagement system to facilitate evidence-based care for child health. Parents, teens and teachers complete questionnaires online from home or waiting room on computers, tablets or phones. Clinicians see results linked to decision support and listings of resources to prescribe. Families view milestones prepopulating their child's individual MemoryBook/CarePortal from the questionnaires, alerts and prescribed resources or search the database. Doctors bill insurance for questionnaires and earn MOC credits. CHADIS documents Meaningful Use and Medical Home requirements. Researchers, insurers and states value CHADIS data. MemoryBook/CarePortal has potential for advertising.	

San Diego,CA|tristantech.com	**Tristan Technologies, Inc.** Medical Devices Alan Sngsaas asingsaas@tristantech.com (858) 550-2700
Tristan Technologies, Inc. is a commercial supplier of laboratory, biomagnetic, geophysical and non-destructive evaluation (NDE) instrumentation. Tristan has significant experience in research, development, fabrication and commercialization of electromagnetic measurement systems. Tristan's products are based on magnetic sensing methods that detect field changes billions of times weaker than the Earth's magnetic field. To accomplish this, we use a device known as a SQUID (Superconducting QUantum Interference Device) that operates at cryogenic temperatures. Tristan formed in 1997 following an employee buyout of the superconducting instrumentation product line of Conductus, Inc. Tristan's original purpose was to fill niche markets including biomagnetic applications.	

Corvallis,OR|viewplus.com	**ViewPlus Technologies, Inc.** Other Gayle Parrish gayle.parrish@viewplus.com (541) 754-4002
ViewPlus was founded in 1996 by Physics Professor John Gardner after he lost his sight. ViewPlus' mission is to develop and market technologies that enable excellent access to all electronic information. ViewPlus embossers produce braille and print the original text and create high resolution tactile graphics, overprinted with the original color images. The hardware and an innovative ViewPlus audio-tactile technology combine to make excellent access to complex graphical information possible. ViewPlus is presently developing interactive self-paced K-6 mainstream educational math/science curricula incorporating these technologies. These curricula are designed to be great for all students, including the "struggling" 40%.	

Birmingham,AL|vistaeng.com	**Vista Engineering Inc.** Medical Devices Raymond Thompson rthompson@vistaeng.com (205) 307-6550
Vista makes diamond coatings and develops products based on our diamond coating technology. We start with a baseline product that is impractical or poorly competitive due to its surface properties. We formulate and apply a diamond coating to the product that elevates the product to the top of its class.	

Waltham,MA|vivonics.com	**Vivonics, Inc.** Medical Devices Anna Galea agalea@vivonics.com (518) 577-4757
The charter of Vivonics is to develop innovative technologies that improve or maintain health, or that optimize the effectiveness of humans in complex systems, from the initial concept through to viable products.	

Salt Lake City,UT|www.microfl.com	**Wasatch Microfluidics** Research Tools Josh Eckman josh@microfl.com (801) 532-4486
Wasatch Microfluidics is a revenue stage company that sells equipment to pharma and biotech companies that outperforms the competition by more than 10 fold in sample throughput. Wasatch has developed a biological printer that "prints" proteins and other biological materials onto surfaces. Wasatch recently signed non-exclusive distribution agreements for worldwide distribution of the CFM Printer. In addition, Wasatch has secured the rights to distribute label free and fluorescent biosensor platforms in North America and Asia in combination with the CFM Printer as turnkey packages. Furthermore, we have a strong product development pipeline for a number of high growth markets.	

 Bethesda,MD|weinbergmedicalphysics.com	**Weinberg Medical Physics LLC** Medical Devices Irving Weinberg inweinberg@gmail.com (301) 346-7944
Weinberg Medical Physics is a four-year-old LLC engaged in research and development, primarily in the field of medical imaging. Our commercialization strategy is to create spin-offs of promising technologies for niche applications, and to license platform intellectual properties that apply to broader markets. Our staff have accomplished both of these goals in the past, having developed medical imaging products that have been used by over 500,000 Americans to date.	

San Francisco,CA|xaludthera.com	**Xalud Therapeutics, Inc.** Biotechnology Peter Heinecke peter.heinecke@xaludthera.com (650) 380-1926
Xalud Therapeutics, Inc. is developing novel therapies for the treatment of neuropathic pain and other neuro-inflammatory diseases. Xalud has been funded in part by a $2.5 Million NIH translation research grant and expects to file an IND for a Phase I/IIa trial in neuropathic pain patients by the end of 2013.	